Brent Pfeiffenberger - Mar 10, 2025 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role
President and CEO, Director
Signature
/s/ Douglas Carr, Attorney-in-Fact
Stock symbol
IPSC
Transactions as of
Mar 10, 2025
Transactions value $
-$1,375
Form type
4
Date filed
3/12/2025, 07:30 PM
Previous filing
Feb 20, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IPSC Common Stock Sale -$1.37K -2.24K -0.19% $0.62 1.19M Mar 10, 2025 Direct F1
transaction IPSC Common Stock Award $0 +522K +43.81% $0.00 1.71M Mar 11, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IPSC Stock Option (right to buy) Award $0 +522K $0.00 522K Mar 11, 2025 Common Stock 522K $0.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Such sales were automatic and not at the discretion of the Reporting Person.
F2 Reflects the grant of RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F3 The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.